Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Trial Profile

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2017 According to a Kalytera Therapeutics media release, application of two clinical sites (Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa) in Israel to commence this study has been submitted to the Institutional Review Boards (IRB).
    • 02 May 2017 According to a Kalytera Therapeutics media release, company plans to initiate this trial in H2 2017 and to be completed over the next 18 months
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top